Published: Oct. 4, 2021 at 12:00 AM HST
NEW YORK, Oct. 4, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that Stacy Lindborg, Ph.D., Executive Vice President and Head of Global Clinical Research, will deliver a presentation at the2021 Cell & Gene Meeting on the Mesa, being held as a hybrid conferenceOctober 12-14, and October 19-20, 2021.
Dr. Lindborg's presentation highlights the expansion of Brainstorm's technology portfolio to include autologous and allogeneic product candidates, covering multiple neurological diseases. The most progressed clinical development program, which includes a completed phase 3 trial of NurOwn in ALS patients, remains the highest priority for Brainstorm. Brainstorm is committed to pursuing the best and most expeditious path forward to enable patients to access NurOwn.
Dr. Lindborg's presentation will be in the form of an on-demand webinar that will be available beginning October 12. Those who wish to listen to the presentation are required to registerhere. At the conclusion of the 2021 Cell & Gene Meeting on the Mesa, a copy of the presentation will also be available in the "Investors and Media" section of the BrainStorm website underEvents and Presentations.
About the 2021 Cell & Gene Meeting on the Mesa
The meeting will feature sessions and workshops covering a mix of commercialization topics related to the cell and gene therapy sector including the latest updates on market access and reimbursement schemes, international regulation harmonization, manufacturing and CMC challenges, investment opportunities for the sector, among others. There will be over 135 presentations by leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering and broader regenerative medicine technologies.
The conference will be delivered in a hybrid format to allow for an in-person experience as well as a virtual participation option. The in-person conference will take place October 12-14 in Carlsbad, CA. Virtual registrants will have access to all content via livestream during program dates. Additionally, all content will be available on-demand within 24 hours of the live program time. Virtual partnering meetings will take place October 19-20 via Zoom.
About NurOwn
The NurOwntechnology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells are designed to effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression.
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwntechnology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has completed a Phase 3 pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). BrainStorm completed under an investigational new drug application a Phase 2 open-label multicenter trial (NCT03799718) of autologous MSC-NTF cells in progressive multiple sclerosis (MS) and was supported by a grant from the National MS Society (NMSS).
For more information, visit the company's website atwww.brainstorm-cell.com.
Safe-Harbor Statement
Statements in this announcement other than historical data and information, including statements regarding future NurOwnmanufacturing and clinical development plans, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may," "should," "would," "could," "will," "expect,""likely," "believe," "plan," "estimate," "predict," "potential," and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, the prospects for regulatory approval of BrainStorm's NurOwntreatment candidate, the initiation, completion, and success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwntreatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture, or to use third parties to manufacture, and commercialize the NurOwntreatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
ContactsInvestor Relations:Eric GoldsteinLifeSci Advisors, LLCPhone: +1 646.791.9729egoldstein@lifesciadvisors.com
Media:Paul TyahlaSmithSolvePhone: + 1.973.713.3768Paul.tyahla@smithsolve.com
Logo- https://mma.prnewswire.com/media/1166536/BrainStorm_Logo.jpg
View original content:
SOURCE Brainstorm Cell Therapeutics Inc
The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.
More:
BrainStorm to Present at the 2021 Cell & Gene Meeting on the Mesa - Hawaii News Now
- Is There Enough Phosphorus for Us? - Discovery Institute - September 8th, 2022
- Types of Tissues Anatomy & Physiology - University of Hawaii - August 22nd, 2022
- Structure and Function - Fish | manoa.hawaii.edu/ExploringOurFluidEarth - August 14th, 2022
- Hotels are offering guests $12,000 stem cell therapies, chewing lessons, and IV drips in luxury wellness kick - Business Insider Africa - July 3rd, 2022
- A major science fair set these scientists on the path to STEM success - Science News for Students - May 15th, 2022
- Immune System: Diseases, Disorders & Function - Live Science - April 19th, 2022
- CellOrigin secured a new round of investment for developing its globally proprietary iPSC-CAR-Macrophage technology platform - Hawaii News Now - October 16th, 2021
- Marine Biologists Are Using Cryopreservation to Save the World's Coral Reefs - Hawaiipublicradio - July 21st, 2021
- Woman Who Was Attacked By Cat Sues the Outrigger Canoe Club in Waikiki - Legal Reader - November 7th, 2019
- Stemming the Tide of Alzheimer's - UCI News - October 9th, 2019
- 20 Strangest Scientific Discoveries Of The Last 20 Years - TheTalko - October 9th, 2019
- CaverStem on the Big Island Giveaway! - EDGEOnTheNet - October 2nd, 2019
- Contact Us - Stem Cell Treatment Center Hawaii - May 14th, 2019
- Stem Cells and Sports Injuries - Honolulu Hawaii - September 5th, 2018
- MushRoaming Hawaii | Mushroaming - Daniel Winkler's ... - June 27th, 2018
- FDA Cracks Down On Stem-Cell Clinics Selling Unapproved Treatments - Hawaii Public Radio-HPR2 - September 4th, 2017
- Yeargan Uses Patients Own Cells To Heal - Greater Wilmington Business Journal - August 27th, 2017
- Pan Pacific Surgical Hawaii Plastic Surgery Symposium - November 27th, 2016
- Cord Blood Banking Cost - Cryo-Cell International - November 25th, 2016
- Stem Cell Therapy - Honolulu Hawaii - Infinity Life Center - November 20th, 2016
- Stem Cell Therapy - Honolulu Hawaii - infinitylifecenter.com - November 18th, 2016
- Stem Cell Treatment Center Hawaii - Stem Cell Treatment ... - September 21st, 2016
- Orthopedic Stem Cell Treatments - Orthopedics - Stem Cell ... - September 15th, 2016
- 6. Hematopoietic Stem Cell ... - University of Hawaii - August 29th, 2016
- Regenexx injections - Stem Cells - The KNEEguru - August 14th, 2016
- Hawaii Stem Cell Treatment Center | Facebook - August 10th, 2016
- Adipose-Derived Mesenchymal Stem Cells; Normal ... - ATCC - October 19th, 2015
- Animal Cells - An educational website all about animal cells - October 1st, 2015
- ASC52telo, hTERT immortalized adipose derived Mesenchymal ... - October 1st, 2015
- How Much Do Stem Cell Treatments Really Cost? | Knoepfler ... - August 9th, 2015
- New Stem Cell Tactic Shows Promise for Heart Failure - August 1st, 2015
- Global Stem Cells Group to Participate in the 15th ... - June 18th, 2015
- Industrial Technology Research Institute Validates ... - June 11th, 2015
- Global Stem Cells Group and Marina Medical Announce ... - June 4th, 2015
- Maui Regenerative Medicine - June 3rd, 2015
- Stem Cell Training, Inc. Announces First European ... - June 1st, 2015
- A Catholic View on Stem-Cell Research - Catholicism and ... - March 13th, 2015
- PowerPoint Presentation - February 23rd, 2015
- Types of Stem Cells - Biology Slideshow - Biology ... - February 2nd, 2015
- Stem Cell Treatment Center Hawaii - Help - Stem Cell ... - October 21st, 2014
- Stem Cell Treatment Center Hawaii - Rules - Stem Cell ... - October 13th, 2014
- Human Cloning and Stem Cells - University of Hawaii - October 3rd, 2014
- Stem Cell Research - Stem Cells and Medicine ... - October 3rd, 2014
- Hawaii (Stem Cell) - what-when-how - August 26th, 2014
- Adult stem cell - Wikipedia, the free encyclopedia - August 23rd, 2014
- Pros & Cons of Embryonic Stem Cell Research - US Liberal ... - August 23rd, 2014
- Stem Cell Therapy Hawaii | Stem Cell Treatments - August 22nd, 2014
- Stem cell treatment gives Honolulu dog better life | More ... - August 22nd, 2014